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Abstract
Background: The presence of poor quality medicines in the market is a global threat on public health, especially in
developing countries. Therefore, we assessed the quality of two commonly used anthelminthic drugs [mebendazole (MEB)
and albendazole (ALB)] and one antiprotozoal drug [tinidazole (TNZ)] in Ethiopia.
Methods/Principal Findings: A multilevel stratified random sampling, with as strata the different levels of supply chain
system in Ethiopia, geographic areas and government/privately owned medicines outlets, was used to collect the drug
samples using mystery shoppers. The three drugs (106 samples) were collected from 38 drug outlets (government/privately
owned) in 7 major cities in Ethiopia between January and March 2012. All samples underwent visual and physical inspection
for labeling and packaging before physico-chemical quality testing and evaluated based on individual monographs in
Pharmacopoeias for identification, assay/content, dosage uniformity, dissolution, disintegration and friability. In addition,
quality risk was analyzed using failure mode effect analysis (FMEA) and a risk priority number (RPN) was assigned to each
quality attribute. A clinically rationalized desirability function was applied in quantification of the overall quality of each
medicine. Overall, 45.3% (48/106) of the tested samples were substandard, i.e. not meeting the pharmacopoeial quality
specifications claimed by their manufacturers. Assay was the quality attribute most often out-of-specification, with 29.2%
(31/106) failure of the total samples. The highest failure was observed for MEB (19/42, 45.2%), followed by TNZ (10/39,
25.6%) and ALB (2/25, 8.0%). The risk analysis showed that assay (RPN= 512) is the most critical quality attribute, followed by
dissolution (RPN= 336). Based on Derringer’s desirability function, samples were classified into excellent (14/106,13%), good
(24/106, 23%), acceptable (38/106, 36%%), low (29/106, 27%) and bad (1/106,1%) quality.
Conclusions/Significance: This study evidenced that there is a relatively high prevalence of poor quality MEB, ALB and TNZ
in Ethiopia: up to 45% if pharmacopoeial acceptance criteria are used in the traditional, dichotomous approach, and 28% if
the new risk-based desirability approach was applied. The study identified assay as the most critical quality attributes. The
country of origin was the most significant factor determining poor quality status of the investigated medicines in Ethiopia.
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Introduction
Intestinal parasites are a diverse group of organisms that
include single-celled protozoans and multi-cellular intestinal
helminths that affect the gastro-intestinal tract of humans and
other animals [1]. Soil-transmitted helminthiasis is caused
primarily by four species of nematodes, i.e. Ascaris lumbricoides
(roundworm), Trichuris trichiura (whipworm), and Ancylostoma
duodenale and Necator americanus (hookworms) that parasitize
human gastrointestinal tract [2]. These major human soil-
transmitted helminths (STH) have significant impact on human
health in many parts of the world, particularly in developing
countries [3]. If not treated early and efficacious, they may lead
to malnutrition, chronic diarrhea, anemia, and other public
health problems that can impair physical and intellectual
development in children [4–6].
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Currently, four drugs are recommended by the World Health
Organization (WHO) for STH: MEB, ALB, levamisole and
pyrantel pamoate [7,8]. MEB and ALB are increasingly deployed
in mass drug administration programs [8] which require a single
drug administration to all subjects without prior diagnosis or
checking for contra-indications. For this reason, the two
benzimidazole 2-carbamates MEB and ALB (chemical structures
presented in S1 Supporting information) are preferred over
levamisole and pyrantel pamoate, which require weight-based
dosing and which are also intrinsically less potent.
Literature reports indicate that TNZ, a 5-nitroimidazole
compound (S1-1 Supporting information), also has some anthel-
mintic efficacy [9], although it is therapeutically mainly used
against protozoan infections and infections caused by anaerobic
bacteria in humans. As such TNZ is often used by the same
patients treated with STH drugs [10,11].
Effective treatment and prevention strategies for these neglected
tropical diseases can be delivered cheaply, but reports of treatment
failure are frequent in developing countries most likely because of
poor quality medicines, which includes spurious/falsely labeled/
falsified/counterfeit (SFFC) medicines, chemical and/or physico-
chemical instability, inappropriate storage and transport, and poor
quality control during manufacturing and importing medicines
[12]. SFFC medicines are medicines that are deliberately and
fraudulently mislabeled with respect to identity and/or source and
include products with the correct ingredients or with wrong
ingredients, without active ingredients, with insufficient or too
much active ingredient, or with fake packaging [13]. Substandard
medicines, i.e. not having the appropriate quality (which is
expected to be equivalent to the regulatory quality), may be SFFC
but also approved medicines. In a quality survey in Nigeria, 48%
of the samples of different categories of medicines were found to be
outside the British Pharmacopoeia (BP) limits for active pharma-
ceutical ingredient (API) assay. Some medicines were even lacking
the active ingredient [14]. The use of substandard medicines may
result in therapeutic failure, resistance development, and occur-
rence of serious adverse events or even death due to excessive dose
or the presence of toxic impurities [15–17]. A study conducted in
sub-Saharan Africa in 2010 on the quality of selected anti-malarial
medicines reported 64% overall quality failure in Nigeria, from
which one artemisinin-based anti-malarial drug sample did not
contain any of artemether API [18].
The presence of substandard and SFFC medicines not only
poses threats to the individual users in terms of the health and side
effects experienced, but also to the public and government in terms
of trade relations and economic implications [19]. Hence, like
many other public health problems, the issue of the presence of
these substandard and SFFC medicines for public consumption
should receive careful attention in developing countries [16].
Finished pharmaceutical products (FPPs) are tested for quality
by assessing whether they meet pharmacopoeial or any other
approved specifications. If not, they are discarded as non-
conforming. This is a dichotomous decision without differentiation
of the seriousness of failure and/or importance of quality attributes
towards clinical use for the patient [20]. The evaluation of quality
of any product poses thus a common problem due to a multiplicity
of measures which must be balanced one against the other. Even
when the quality attributes are precisely measurable, a serious
challenge exists in combining the individual measurements into
one index representing the total quality [21]. Such balance
problems can be solved by using a Derringer’s desirability function
[22].
In general, this study was carried out to assess the pharmaco-
poeial quality of three medicines (MEB, ALB and TNZ)
circulating in Ethiopia. The quality in terms of quality attributes
like assay/content, dosage uniformity, dissolution, disintegration
and friability was evaluated. The criticality of the quality attributes
was assessed using FMEA risk-based analysis and Derringer’s
desirability function was applied to obtain one global quality index
for each sample investigated.
Methods
Materials
MEB USP working standard [Cadila Pharmaceuticals (Ethio-
pia)], ALB reference standard [Greenfield Pharmaceuticals
(China)] and TNZ reference standard [Greenfield Pharmaceuti-
cals (China)] were kindly donated from Food, Medicine and
Health-care Administration and Control Authority (FMHACA) of
Ethiopia and used as received. Purified ultra pure water was
obtained by water purification system (Thermofischer Scientific,
USA, 18.2 MV.cm at 25uC). All other chemicals used in this study
were analytical grade and used as received.
Sample collection
The sampling strategy was defined following the Medicine
Quality Assessment Reporting Guidelines (MEDQUARG) as
proposed by Newton PN et al., 2009 [23] based on the questions:
‘‘Are there medicines of poor quality in the formal distribution
outlets in Ethiopia? If there are, what is the prevalence of these
poor quality medicines?’’ Moreover, since there is a possible
influence of origin and distribution conditions on medicines
quality as received by the patient, we included the different formal
outlets that are in practice used by patients in Ethiopia. So, we also
looked at the following question: ‘‘Is there a difference in quality of
medicines (1) among the different levels of medicines outlets? (2)
across different geographic areas of the country? (3) among the two
national economies: government and privately owned medicines
outlets and (4) among the different countries of origin’’. Therefore,
in function of the questions, sampling units were defined to be the
medicines sold from the drug retail outlets of the formal supply
chain in the country, the different levels of the supply chain system
Author Summary
Access to medicines of good quality improves the chances
of successful treatment for individual patients and
promotes better outcomes for public health in general.
At present, the prevailing strategy for improving access to
medicines for neglected tropical diseases (NTDs) is drug
donation programs. However, the presence of poor quality
medicines in the market is a global threat on public health,
especially in developing countries by critically risking
efforts of treatment and control of diseases in general and
the NTDs in particular. Conventionally, medicine quality
has been ignored in NTDs, though scattered reports show
that serious problems exist. Therefore, we assessed the
quality of two commonly used anthelminthic drugs (MEB
and ALB) and one antiprotozoal drug (TNZ) in Ethiopia. The
analytical results were converted into conclusions using
two systems: the traditional dichotomous pharmacopoeial
specification-compliance based approach and the risk-
based Taguchi quantitative desirability approach. Overall,
the results showed high prevalence of poor quality of the
three medicines, mainly determined by the country of
origin. We conclude that risk-based regulatory quality
control procedures should be based on identification of
the most critical quality attribute and apply desirability
functions to quantify and classify the quality of medicines.
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in Ethiopia (drug stores incl. health centers, pharmacies incl.
hospital pharmacies, wholesalers), the geographic areas, govern-
ment/privately owned medicines outlets and country of origin.
Based on the sampling strategy, 106 drug samples were
collected between January and March 2012 through multilevel
stratified random sampling from all the levels of the supply chain
system of the country (n = 3) covering all types of government and
privately owned drug outlets (n = 2). All available drug samples of
the three study medicines were collected from each of the selected
drug outlet. Through proportional allocation to each stratum of
the supply chain, 59.4% (n = 63) of the drug samples were
collected from drug stores; 36.8% (n = 39) were from pharmacies
while the remaining 3.8% (n = 4) samples were from wholesales.
17.9% (n = 7) of pharmacy collected drug samples were obtained
from hospitals, while four of the drug samples collected from drug
stores was from health centers. Depending on the geographic
locations and drug markets, the samples were collected from 7
major cities of the country: Addis Ababa, Hawasa (and its region
including Arbaminch and Shashemene), Jimma, Assosa (and its
region including Nekemte), Adama, Mekele and Bahirdar; which
represent all four directions starting from Addis Ababa, the major
central commercial center. All samples were tablet formulations
and purchased anonymously by mystery shoppers from local area
who were trained before. The mystery shoppers stated, if needed,
that they were a travelling five member family and the family
head, a man of 35 years old, abruptly caught a stomach ache
(‘kurtet’ in Amharic) due to worm infestations and requested the
dispenser at the medicine outlet for some mebendazole (for
‘kurtet’) and albendazole tablets (for ascariasis) as he used both
medicines from his past experiences. At the same time, the family’s
18 years old son was suffering from diarrhea and thus requested
the dispenser for any medicines which could be given for him
describing that he was taking tinidazole tablets two months ago for
similar symptoms. Since the travelling family was in a worry of
coming up with shortage of the medicines while travelling they
requested a sufficient quantity of tablets of the medicines.
The mystery shoppers were blinded about the purpose of the
study and only instructed to purchase medicines in their original
primary packaging as supplied by the manufacturer. For the
purpose of this study, the relevant information of all collected
samples was recorded on a standard form as soon as leaving the
drug outlet and entered into database. The information included
the level of the drug outlet, place/city of collection, name of the
active pharmaceutical ingredient, the country of origin, manufac-
turing company, expiry date, manufacturing date, batch/lot
number, and labeled dose (strength) of the active ingredient.
Medicines purchased from a specific outlet, labeled with a specific
generic name or brand name, strength, number of units per strip/
package, batch number, country of origin, manufacturing and
expiry dates were considered as one sample. Since the mystery
shoppers stated that they were a travelling five member family,
they were able to buy enough units per sample. For MEB, 50
tablets per sample were purchased while for ALB and TNZ, a
sample contained 100 tablets. The samples were stored at ambient
temperature (20uC to 25uC) until tested, with a storage period of
maximally 3 months before testing, and none of samples had
expired at the time of testing.
Test methods for products quality
The quality control laboratory tests were performed in Jimma
University Laboratory of Drug Quality (JuLaDQ), Jimma,
Ethiopia. JuLaDQ follows a quality system extended from its
collaborating laboratory, Laboratory of Drug Quality and
Registration (DruQuaR) of Ghent University, 9000-Ghent,
Belgium.
The laboratory tests were carried out according to the general
and individual monographs specified in different Pharmacopoeias,
as indicated in S1-2 supporting information.
Instrument performance and system suitability tests were
successfully performed for the analytical instruments and HPLC
methods, respectively.
For any drug product, identification of the active pharmaceu-
tical ingredient (API) is a critical quality attribute. The three drugs
(ALB, MEB and TNZ) belong to biopharmaceutical classification
system (BCS) class II, with low aqueous solubility and high
permeability [24,25]. Moreover, disintegration is an integral part
of and/or pre-requisite for dissolution of immediate release dosage
forms [26].
Therefore, quality attributes based upon which the products
were evaluated were defined to be identification, assay/content,
dissolution, dosage uniformity, disintegration and friability tests.
Quality failure was defined as a sample failing any single test of the
aforementioned tests for which it was evaluated.
Details of the laboratory test methods used to evaluate the study
medicines are presented in S1-3 supporting information.
Risk analysis
Risk analysis is a general quality tool which has its roots in
engineering [27], but is now becoming a well-established tool in
the pharmaceutical field as well. As such, ICH has devoted a
separate guideline (Q9) to quality risk management, which is being
embraced by pharmaceutical authorities [28]. Risk analysis, i.e.
the estimation of the risk associated with the identified hazards, is
an important part of this global risk management. Several quality
risk management tools like FMEA (Failure Mode Effects Analysis)
are available, as mentioned by ICH in Q9. Therefore, FMEA was
used to evaluate the criticality of product quality attributes in this
study. Criticality was evaluated using RPN, based on evaluations
about the probability of occurrence of the failure (O), the severity
of the failure (S) and the probability of not detecting the failure (D).
These judgments are converted into numerical values using
descriptive scales and finally combined in the RPN [29] by means
of Equation (1):
RPN~O:S:D ð1Þ
Used scales for severity, occurrence and detectability of failure
are presented in Tables 1 to 3 [30]. For severity ratings, five
pharmaceutical experts in Belgium (4) and Ethiopia (1) (S1-4
supporting information) were assigned to score it and the median
score was taken. For occurrence, literature was reviewed for the
three products (MEB, ALB and TNZ) in Africa and for other
drugs in Ethiopia as there was no previous quality study conducted
for these three products in Ethiopia. In Nigeria, 48% of MEB
samples contained amounts of active ingredient outside the
appropriate assay limits [31]. Assay based pharmaceutical quality
assessment in Kenya reported very poor quality for majority of
marketed anthelmintic preparations [32]. Therefore, the highest
occurrence score of 8 was assigned for assay. Studies conducted in
Ethiopia indicated that the occurrence of failure of identification,
disintegration and friability tests are very low making the scores
assigned to each of these failures to be 1 [18,33,34]. Since 19.1%
(8/42) of our MEB samples did not meet the pharmacopoeial
acceptance criteria for dosage form uniformity, the probability of
occurrence of this failure is moderately high and thus a score of 6
was assigned for its occurrence. For scoring the detectability, the
Quality of Medicines for STH and Giardia
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scaling ranged from the low score assigned to the easiest detection
to the highest score for the more difficult detection method.
Friability can be detected through simple visual/weighing
observation; hence, a score of 1 was assigned to its detectability.
On the other hand, assay and dissolution studies involve
quantitative tests, requiring fully equipped laboratory system and
trained personnel. Therefore, detectability was scored to be 8 for
each of these failure modes. Since identification requires field tests
like color reactions and/or TLC, a score of 5 was assigned to
detectability of identity failures.
Desirability function
Desirability function, just like risk analysis, is a quality tool first
proposed by Harrington in 1965 for use in the optimization of
quality of manufactured products. The approach has basic
foundation in engineering [35,36] and is widely adopted in the
manufacturing industry.
The central idea of a desirability function is to create one ball-
mark figure. which is a composite number reflecting different
response. This is done by mapping the value of each property/
response onto a unit-less score in the range from zero to one based
on the appropriateness (or desirability) of the property/response.
Therefore, Derringer’s desirability function was applied for the
assessment of the quality of the three pharmaceutical products
(MEB, ALB and TNZ). The desirability function can be used to
combine multiple responses into one response called the ‘‘overall
desirability function’’ D, ranging between a value of 0 (one or more
product characteristics are completely unacceptable) to 1 (all
product characteristics are on target). This overall desirability
function D is obtained from the geometric mean of the individual
desirabilities (di) which provide a way to assess the quality of one
property. The formula to calculate the overall D-value is presented
in Equation 2:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P
n
i~1
d
pi
i
n
q
ð2Þ
In this equation, pi was the weight or relative importance
assigned to the response. For this study, n equals 4 since four
characteristics were considered in the global evaluation of ALB
and TNZ, while n = 3 for MEB since dissolution study was not
performed. The advantage of calculating the geometric mean is
that when one of the criteria has an unacceptable value, the overall
product will be unacceptable as well. The highest global
desirability value represents the product with the highest quality.
Individual desirability functions were defined for each of the
quality attributes, based on a psychophysical scale and the results
obtained from the FMEA quality assessment. Desirability function
possessing values in the range (0–1) classifies the conversion of the
quantity value of a specific quality indicator into the assessment of
Table 1. Evaluation criteria and ranking system for the severity of effects.
Effect Criteria: severity of effect Rank
Hazardous Failure is hazardous, and occurs without warning. It suspends operation of the system 10
Serious Failure involves hazardous outcomes and/or noncompliance with government regulations or standards 9
Extreme Product is inoperable with loss of primary function. The system is inoperable 8
Major Product performance is severely affected but functions. The system may not operate 7
Significant Product performance is degraded. Comfort or convince functions may not operate 6
Moderate Moderate effect on product performance. The product requires repair 5
Low Small effect on product performance. The product does not require repair 4
Minor Minor effect on product or system performance 3
Very minor Very minor effect on product or system performance 2
None No effect 1
doi:10.1371/journal.pntd.0003345.t001
Table 2. Evaluation criteria and ranking system for the occurrence of failure.
Probability of failure Possible failure rates Rank
Extremely high: failure almost inevitable §1 in 2 10
Very high 1 in 3 9
Repeated failures 1 in 8 8
High 1 in 20 7
Moderately high 1 in 80 6
Moderate 1 in 400 5
Relatively low 1 in 2000 4
Low 1 in 15,000 3
Remote 1 in 150,000 2
Nearly impossible !1 in 1,500,000 1
doi:10.1371/journal.pntd.0003345.t002
Quality of Medicines for STH and Giardia
PLOS Neglected Tropical Diseases | www.plosntds.org 4 December 2014 | Volume 8 | Issue 12 | e3345
the desirability (preference) of a certain condition of evaluated
subject (pharmacopoeial quality of the three medicines). Among
the specific ways to implement the desirability function for the
corresponding estimation, a psychophysical scale of Harrington is
chosen providing universal application. The scale served to
establish the correspondence between physical and psychological
parameters. All the numeric desirability values (0–1) of the
measured parameters/quality attributes are regarded as physical
parameters, while a purely subjective assessment of a researcher
(e.g. excellent, good, acceptable, low, bad) to express degree of
satisfaction are regarded as psychological parameters.
A rough estimation constructs a five–interval quality scale
(Table 4) [37]. For assay and dissolution, a two-sided desirability
function was used where it becomes zero at the lowest and upper
limit. For identity and dosage form uniformity, a one-sided
desirability function was used. Absence of API is assumed to be
clinically completely undesirable and thus this point was assigned
d = 0 where as 100%lc was assigned d = 1 (i.e. optimal desirability).
Since the pharmacopoeial specification for assay is 90–110%lc for
all the three products and the pychophysical Harrington’s scale of
quality specifies desirability range from about 0.7 to 1.0 to be
good, d = 0.7 was assigned for assay values of 90 and 110%lc.
Moreover, d = 0.3 was assigned for both 70% and 130%lc, while
d = 0.01 was assigned to 50% and 150%lc. The individual
desirability function for assay was then defined as different linear
sections of different slopes in the range of 100%lc to 90%lc
(slope = 0.03), 90%lc to 70%lc (slope = 0.02) and from 70%lc to
50%lc (slope = 0.01). Similar but negative slopes were used for
assay values greater than 100%lc, mirroring the under-dosing
profile.
For dissolution, %drug release was considered. According to
USP acceptance criteria (S1-2 supporting information), ALB
should release 80% within 30 minutes, while TNZ should release
75% within 120 minutes. However, BP sets acceptance criteria for
both drugs at 70%. Therefore, d = 1 was assigned for 100% drug
release, while d = 0.7 was assigned for the average 75% and 125%
drug release for both ALB and TNZ. Moreover, d = 0.3 was
assigned for both 50% and 150% drug release, while d = 0.01 was
assigned to 40% and 160% drug release.
For dosage uniformity, the relative standard deviation (RSD)
was considered as response. According to Ph. Eur. (2012), RSD
should be not more than 2%; and thus d = 1 was assigned for
RSD = 0% while d = 0.7 for RSD = 2%. Following Harrington’s
scale, d = 0.3 was assigned for RSD of 6% and d = 0.01 for RSD of
15%; while for RSD = 25%, d was assigned to be 0.
For identity, d = 1.0 was assigned for those complying with
pharmacopoeial specifications for identity and d = 0 for those
which do not comply.
Data analysis
Data entry and analysis was carried out using Statistical Package
for Social Sciences software (version 16.0 for windows; SPSS). The
assay was carried out in triplicate and data were expressed as mean
values. The Fisher exact test was used to test the association of the
binary quality attributes with the country of origin (5 origins),
collection sites (7 cities) and drug outlets (3 types). A more detailed
statistical data analysis, based on the fixed effects model with
different response variables (product quality attributes) and
different categorical covariates derived from our sampling strategy
questions was done. FMEA was used to assess the criticality of the
quality risks associated with each quality attribute and Derringer’s
Table 3. Evaluation criteria and ranking system for the detection of a cause of failure.
Detection Criteria: likelihood of detection by design control Rank
Absolute uncertainty Design control does not detect a potential cause of failure or subsequent failure mode; or there is no design control 10
Very remote Very remote chance the design control will detect a potential cause of failure or subsequent failure mode 9
Remote Remote chance the design control will detect a potential cause of failure or subsequent failure mode 8
Very low Very low chance the design control will detect a potential cause of failure or subsequent failure mode 7
Low Low chance the design control will detect a potential cause of failure or subsequent failure mode 6
Moderate Moderate chance the design control will detect a potential cause of failure or subsequent failure mode 5
Moderately high Moderately high chance the design control will detect a potential cause of failure or subsequent failure mode 4
High High chance the design control will detect a potential cause of failure or subsequent failure mode 3
Very high Very high chance the design control will detect a potential cause of failure or subsequent failure mode 2
Almost certain Design control will almost certainly detect a potential cause of failure or subsequent failure mode 1
doi:10.1371/journal.pntd.0003345.t003
Table 4. Modified psychophysical Harrington’s scale of quality and results of risk-based desirability function approach.
# Intervals in global desirability (D-global) Quality, descriptive evaluation Number of products in each quality scale (percentage)
1 0.90–1.00 Excellent 14 (13%)
2 0.80–0.90 Good 24 (23%)
3 0.70–0.80 Acceptable 38 (36%)
4 0.37–0.70 Low* 29 (27%)
5 0.00–0.37 Bad* 1 (1%)
*Unacceptable qualities.
doi:10.1371/journal.pntd.0003345.t004
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desirability function was applied to evaluate quality of the
products.
Results
Quality of the investigated products
A total of one hundred and six samples of MEB, ALB and TNZ
were collected between January and March 2012 in seven major
cities that represent most parts of the country considering
pharmaceutical market and geographic areas. The samples had
been collected from 38 premises (wholesales, pharmacies and drug
stores). Of these, 42 samples were MBZ, 25 samples were ALB and
39 were TNZ samples. The origin (place of manufacturing) of
samples was domestic and foreign (China, India, Korea, and
Cyprus). Domestic products constituted 45.3% (48/106), followed
by Indian products with 26.5% (28/106). All samples had the
intended active ingredient as demonstrated by the positive
identification tests. No gross mislabeling (incorrect, inadequate
or incomplete identification) was observed for the samples.
However, the quantitative laboratory experiments indicated that
45.3% (48/106) of the samples did not meet the expected
pharmacopoeial quality specifications: 45.2% (19/42) MEB,
48.0% (12/25) ALB and 43.6% (17/39) TNZ samples. The
results of the different quality control tests of the samples are
presented in Table 5 and are detailed below.
Assay. The assay values for MEB drug products ranged from
68.6 to 132.9%lc (mean: 106.2%), while that of ALB ranged from
87.1 to 111.0%lc (mean: 98.6%). For TNZ drug products, the
assay values ranged from 86.1 to 120.6%lc (mean: 105.7%). A box
plot of assay by product type, country of origin, supply chain and
place of collection is indicated in Fig. 1 and assay test results by
product brand is presented in Table 6.
This study revealed that 29.2% (31/106) of samples did not
meet the pharmacopoeial acceptance specification for the assay,
and thus are formally classified as substandard medicines [13]. A
high failure rate, 45.2% (19/42) was found for MEB tablets
followed by TNZ with failure rate of 25.6% (10/39) and 8.0% (2/
25) of ALB samples. From those 31 samples failing to meet the
official specification limit for assay, 80.7% (25/31) of the samples
were over-dosed and 19.4% (6/31) were under-dosed. MEB
samples showed the highest variation for assay test with a relative
standard deviation (RSD) of 12.5%, followed by TNZ and ALB
with RSD 6.7% and 4.8% of the labeled amount, respectively.
Considering the time left to expiry date, all ALB samples expired
in 2013, while for MEB and TNZ, the expiry date was longer, i.e.
2015/16, which can explain the difference in assay values between
the 3 drug product classes.
The assay results reveal that the majority of the failed samples
contain too much active ingredient that may be introduced
intentionally during production (i.e., overages applied). However,
as a general principle, use of an over-dose of a drug substance to
compensate for loss during manufacture or degradation during a
product’s shelf life to extend its shelf life, is discouraged [38].
Disintegration test. In this study, all tablet samples met the
official requirement for disintegration time test.
Dissolution test. As shown in Table 5, from 19 ALB and 39
TNZ samples tested for their in-vitro dissolution, 42.1% (8/19) of
ALB and 17.9% (7/39) of TNZ samples failed to meet the official
tolerance limits. There is a significant difference between countries
of origin with respect to the in-vitro dissolution profile, with all
samples manufactured in Ethiopia (19/19) meeting the official
tolerance limit and 25.9% (15/58) failure rate observed for the
imported products. From the 11 products (4 ALB and 7 TNZ)
purposefully selected for the release profile study, all three ALB
brands released more than 80.0%lc in 30 minutes except one ALB
generic product but a fast release was revealed from one product
in which 74.0%lc was released within 10 minutes as presented in
Fig. 2. All four TNZ brands and three generic products released
more than 75.0%lc of the dose within 120 minutes as indicated in
Fig. 3.
Dosage uniformity. Dosage uniformity is measured to
ensure a constant dose of drug between individual dosage forms.
All ALB and TNZ samples were in line with pharmacopoeial
acceptance criteria for dosage uniformity, but 19.1% (8/42) of
MEB samples did not meet these specifications as indicated in
Table 5.
Friability test. A relatively high failure rate (20%) of ALB
samples followed by TNZ (7.7%) and MEB (7.1%) was observed in
the present study. Overall 10.4% (11/106) of samples failed to
meet the friability test (S1–2 Supporting information). The higher
friability for ALB products might be related to the rapid
disintegration and dissolution of these products.
Risk analysis
The results of the RPN values after scores assigned for severity,
occurrence and detectability of the failure mode are presented in
Table 7. In the quality attributes subjected to FMEA, a total of 5
failure modes with RPN scores ranging from 2 to 512 were
identified. Risk analysis showed that assay (RPN = 512) is the most
critical quality attribute followed by dissolution (RPN = 336) and
dosage uniformity (RPN 144). Friability was found to be the
quality attribute of the least concern according to FMEA analysis
applied to product quality assessment.
Derringer’s desirability function
The results of individual desirability values di and the overall
desirability D are presented in the S2 supporting information. The
individual desirability values assigned to the different segments
were fitted to the segmented linear model as indicated in Fig. 4.
Table 5. Pharmacopoeial quality test results by product.
Product and strength (mg) Samples failing quality parameters test
Assay Dissolution Dosage uniformity Friability Overall
ALB (400) 8% (2/25) 42% (8/19) 0% (0/25) 20% (5/25) 48% (12/25)
MEB (100) 45% (19/42) - 19% (8/42) 7% (3/42) 45% (19/42)
TNZ (500) 26% (10/39) 18% (7/39) 0% (0/39) 8% (3/39) 44% (17/39)
Overall 29% (31/106) 26% (15/58) 7% (8/106) 10% (11/106) 45% (48/106)
- Not performed.
doi:10.1371/journal.pntd.0003345.t005
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For each medicine analyzed for the retained 4 quality attributes
(assay, dissolution, dosage form uniformity and identity), a global
D was finally calculated using the above mentioned d-functions
and evaluated using the psychophysical Harrington’s scale of
quality as presented in Table 4. According to this scale, it was
revealed that 13.2% (14/106) of the products were excellent, while
22.6% (24/106) were good and 35.8% (38/106) were of
acceptable quality. Thirty products (28.3%) were found to be of
unacceptable quality (low and bad). Moreover, the distribution of
the D-values among the investigated products is presented in
Fig. 5.
Discussion
To address the subject of quality of medicines, different
internationally accepted semantics and definitions are used. In
this study, the semantics ‘‘poor quality’’ was used due to the
following reasons:
1) We did not find obvious features which suggest that the
investigated samples were counterfeit, falsified and/or unreg-
istered; although we did not explicitly search for counterfeits,
falsified and/or unregistered medicines. Therefore, without a
detailed investigation involving the manufacturer, distribu-
tion-chain and health authorities, it is impractical to rule out
this perspective.
2) Poor quality can have good manufacturing practice (GMP)
and/or good distribution practice (GDP) reasons, and as such,
we do not differentiate explicitly between GMP-substandard
(at manufacturer) versus degraded substandard (while being
good quality at manufacturer). In this study, it was not
practical to easily differentiate if poor quality was due to weak
GMP or rather inadequate GDP. Moreover, the WHO as
well as US-IOM (institute of medicine), and recent expert
opinions [39] do not make this distinction and prefer to use
the term ‘substandard’ to address both. Finally, quality does
also include the intrinsic stability of the medicine (a very
important aspect in tropical climates), which is a function of its
composition, quality of ingredients/packaging and manufac-
turing process [40].
3) Even though the term ‘substandard’ literally means ‘‘under
the standard’’, it is obviously related to a legally required
specification mostly interpreted in the national regulations in
Fig. 1. Box plot for assay versus (a) product type, (b) origin, (c) premise/supply chain and (d) place of collection. Numbers are given
between the brackets.
doi:10.1371/journal.pntd.0003345.g001
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the approved marketing registration file and/or national
pharmacopoeia/compendia, where some still use other
quality standards, e.g. Ph.Int. or USP-MC. They all differ
not only in quality attributes and methods, but also in
acceptance criteria as well. As in Low and Middle Income
Countries (LMIC), the legally required standards are often
absent and incomplete. Therefore, we prefer to use ‘‘poor
quality’’ over ‘‘substandard’’, as for the investigated products,
we were not aware of the legally binding national Ethiopian
quality standards. Moreover, we did not only use more
international quality specifications, but also wanted to
introduce the Taguchi-concept in our quality-evaluation, thus
(to some extent) avoiding the ‘‘standard’’ issue, with an on-off
decision, and replacing it by a quantitative quality number.
4) While other semantics like (S)SFFC, fake, and the like are
sometimes used, we believe in accordance with EMA, US-
IOM, and recent expert opinions, that for the purpose of this
study, a simple 2-dimensional division between falsified and
substandard will be sufficient.
In this study, we conducted quality evaluations based on two
different approaches: the conventional viewpoint (dichotomous
decision based on arbitrarily pharmacopoeial acceptance limits)
and the risk-based desirability function approach. The conven-
tional perspective is based on the acceptance criteria set in general
and individual monographs of different pharmacopoeias and
guidelines, while the desirability function approach is based on
quality-by-design (QbD) and risk-based principles whereby clinical
relevance is a key factor. A medicine can have many different
quality attributes, which are certainly not equally important, i.e.
each quality attribute has a different criticality for the clinical use
of the medicine. This ICH-recommended risk-based approach is
derived from the Taguchi quality philosophy, where any deviation
from the optimal point is considered as a less optimal situation and
there is no dichotomous decision (see S1-4 Supporting Informa-
tion).
Therefore, this study reports not only the percentage compliant
with the generally accepted pharmacopoeial specification limits for
each of the quality attributes using the conventional, dichotomous
approach, but also derived a global quality number which
encompasses the clinical importance of the different quality
attributes. This clinical importance, i.e. criticality or risk if
deviating from the optimum, was assessed by quality risk tools:
within FMEA, one uses the risk priority number (RPN) to estimate
this risk.
Conventional quality of investigated medicines
In general, the prevalence of poor quality medicines was the
highest for ALB tablets (48.0%, 95% CI: 28.4 to 67.6), followed by
MEB (45.2%, 95% CI: 30.2 to 60.3) and TNZ (43.6%, 95% CI:
Table 6. Assay test results by product type.
Drug products (n) Brands (n) Minimum Maximum Mean SD Median
MEB (42) M1 (14) 98.6% 131.1% 108.6% 9.7% 106.6%
M2 (14) 68.6% 132.9% 107.6% 17.2% 107.7%
M3 (7) 81.0% 109.4% 95.0% 10.3% 93.0%
M4 (5) 98.7% 115.6% 105.8% 7.4% 102.2%
M5 (1) 121.1% 121.1% 121.1% NA 121.1%
M6 (1) 118.7% 118.7% 118.7% NA 118.7%
Sub total 68.6% 132.9% 106.2% 13.3% 106.0%
ALB (25) A1 (1) 92.0% 92.0% 92.0% NA 92.0%
A2 (9) 96.7% 108.0% 99.2% 3.5% 97.9%
A3* (6) 94.2% 102.4% 97.5% 3.1% 96.4%
A4 (2) 99.5% 103.3% 101.4% 2.7% 101.4%
A5 (1) 104.0% 104.0% 104.0% NA 104.0%
A6 (3) 87.1% 100.0% 95.3% 7.1% 98.8%
A7 (1) 96.3% 96.3% 96.3% NA 96.3%
A8 (1) 94.3% 94.3% 94.3% NA 94.3%
A9 (1) 111.0% 111.0% 111.0% NA 111.0%
Sub total 87.1% 111.0% 98.6% 4.8% 97.9%
TNZ (39) T1 (3) 86.1% 99.1% 94.7% 7.5% 99.1%
T2 (7) 107.7% 112.0% 108.9% 2.1% 107.7%
T3* (5) 99.1% 112.0% 104.2% 4.7% 103.4%
T4* (9) 99.1% 107.7% 102.4% 2.9% 103.4%
T5 (8) 99.1% 120.6% 113.6% 7.6% 114.1%
T6 (5) 94.8% 103.4% 101.6% 3.9% 103.4%
T7* (2) 107.7% 107.7% 107.7% 0.0% 107.7%
Sub total 86.1% 120.6% 105.7% 7.0% 103.4%
Total (106) 68.6% 132.9% 104.2% 10.1% 103.4%
*Generic products; SD = Standard deviation; NA= Not applicable.
doi:10.1371/journal.pntd.0003345.t006
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Fig. 2. Comparative in-vitro release profile studies of four different products of albendazole (ALB) tablets. All data points presented are
mean values of triplicate experiments (n = 3) and error bars indicate standard deviations. Percent drug release should be between 70 and 130% within
30 min.
doi:10.1371/journal.pntd.0003345.g002
Fig. 3. Comparative in-vitro release profile studies of different products of tinidazole (TNZ) tablets. All data points presented are mean
values of triplicate experiments (n = 3) and error bars indicate standard deviations. Percent drug release should be between 70 and 130% within
120 min.
doi:10.1371/journal.pntd.0003345.g003
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28.0 to 59.2) tablets (Table 5). Overall, 45% (48/106) of the
analyzed drug samples failed to meet the official tolerance limits
for assay, dissolution, friability and uniformity of dose.
A similar survey conducted on anti-malarial drugs in Senegal,
Madagascar and Uganda identified 44%, 30%, and 26%
substandard anti-malarial drugs, respectively [41]. Assay and
dissolution profile study for anti-malarial samples conducted in
south-east Nigeria reported 37% substandard medicines [42].
Assay based pharmaceutical quality assessment in Kenya reported
that many anthelmintic preparations marketed in Kenya were of
very poor quality [32].
The probable causes for the presence of poor quality medicines
in developing countries like Ethiopia might be due to poor storage
conditions, insufficient quality assurance, poor compliance with
good manufacturing practice standards, lack of scientific expertise
in manufacturing sector, limited technical capacity and insuffi-
ciently well developed regulatory system to evaluate and take
action to solve the problems related to drug quality [43].
From those drug samples collected from pharmacy, about
51.1% (24/46) failed while 46.9% (23/55) and 20.0% (1/5) were
the failure rates for those collected from drug store and wholesale,
respectively. Even though the sample size was small to generalize,
Fig. 4. Linear desirability functions: (a) assay (%label claim), (b) dissolution (%drug release), (c) dosage uniformity (%RSD) and (d)
identity (compliance to specification).
doi:10.1371/journal.pntd.0003345.g004
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there was significant difference in the pharmacopoeial quality
parameter of medicines between the country of origin (P,0.05)
but there was no significant association for place of collection and
outlets, P.0.05 as presented in Table 8 and Fig. 1.
Regarding the collection areas, a high failure rate was observed
for samples collected from Addis Ababa, Jimma and Adama areas.
Since these areas are commercial centers due to their geographic
location, it requires special attention by the regulatory offices to
control the circulation of these anthelmintic medicines to combat
poor quality medicines circulation.
All analyzed samples contained the intended active ingredient.
Even though a single case of API-absent medicine is unacceptable,
the finding of this study was good as compared to other studies,
e.g. in Cambodia (4.2%) [44]. However, 29.2% (31/106) of the
samples did not comply with the pharmacopoeial acceptance
criteria for assay. Of the MEB samples, 45.2% were found to be of
poor quality with respect to assay as per the official tolerance limit.
This result is in agreement with the study conducted in Nigeria’s
pharmacies in which 48% samples of MEB did not comply with
set pharmacopoeial limits [31]. On the other hand, ALB samples
showed relatively better compliance but still unacceptable as 8.0%
did not meet the official acceptance limit for assay. In general,
from those drug samples which failed assay test, 19.4% (6/31)
were under-dosed. One of the contributing factors for the
development of drug resistance is under-dosing due to poor
quality medicines [45].
Uniformity of dosage unit is defined as the degree of uniformity
in the amount of active substance among individual dosage units.
Content uniformity depends on a number of formulations and
manufacturing processes, hence it is obviously unrealistic to
presume that every unit contains exactly the same amount of the
active ingredient as indicated on the label. Therefore, pharmaco-
poeial standards and specifications have been established to
provide generic limits for allowable variations for the active
ingredients in single dosage units considering fitness-for-use and
production capability considerations [46]. It was previously
reported that (single dose) ALB is more efficacious against
hookworm than (triple dose) MEB [47], which may partly be
explained by our quality results revealing that all ALB and TNZ
samples fulfill the acceptance criteria for dosage uniformity while
19.1% (8/42) of MEB samples did not meet these pharmacopoeial
acceptance criteria.
Friability test is conducted to check whether the weight loss
during handling is within 1.0% loss specification limit. As
indicated in Table 5, 5 ALB, and 3 MEB and 3 TNZ tablet
samples failed the pharmacopoeial acceptance criteria of friability.
The percent weight loss for all the drug samples failing the
specification criteria ranges between 2.2 to 6.0%, where the largest
Fig. 5. Distribution of D-values among the investigated products.
doi:10.1371/journal.pntd.0003345.g005
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weight loss was registered from a MEB tablet sample. Taking into
consideration the single dose regimen and the already substandard
drugs with content less than 90%lc, this maximum weight loss
from friability study by MEB sample could further pose more risk
of drug resistance leading to treatment failure than the other two
drugs, ALB and TNZ.
In the present study, since all the drug samples tested for
disintegration have met the pharmacopoeial acceptance criteria,
there is no risk associated with disintegration as a quality attribute.
However, 42% of the ALB samples and 18% of the TNZ samples
which were tested for dissolution have been found to be out of the
pharmacopoeial specification limit. For low solubility drugs, raw
material and process variables could have impact on clinical safety
and efficacy through their effects on dissolution. Therefore, the
risk of clinical failure is higher for ALB than TNZ as more delayed
dissolution was observed, which could be due to changes in the
drug substance particle size, failure to control granulation, and
increased level of binder in the formulation [48].
The information available on the effectiveness of various BZs
derivatives (e.g. ALB and MEB) is somewhat inconsistent [49,50].
Thus the observations of different therapeutic outcomes have been
to some extent attributed to the different polymorphs with
different dissolution rates and anthelmintic activities. Solid-state
properties play crucial role in dissolution rate and solubility,
especially when different polymorphs are involved affecting the in-
vivo performance of the drugs [51–54]. For example, MEB exists
as polymorphs and solvates in the solid state. Of particular
importance is the difference in the physicochemical properties of
the three known polymorphs A, B, and C. The polymorphic forms
of MEB display significant differences in solubility and therapeutic
efficacy and form C is preferred clinically due to its optimal
bioavailability and reduced toxicity. This is important because
polymorph A has no anthelmintic activity alone or when present
above 30% in polymorphic mixtures. Literatures indicate that at
temperatures typically found in countries located in ICH climatic
zones III (hot and dry) and IV (hot and humid) trace amounts of
form A in tablets significantly accelerate the transformation of the
clinically active polymorph C to form A. This transformation
significantly reduces the shelf lives and the dissolution rates of
these tablets [55].
ALB also exhibits some polymorphic forms by forming solvated
crystals. Each of these crystals, including the un-solvated form,
may exhibit all the aspects of polymorphism. However, solid state
characterization of ALB indicated that both forms are physically
quite stable [51]. A literature report indicated that TNZ also
exhibits crystal polymorphism [56].
Regarding the use of ALB or MEB, specific attention should be
given to the dose appropriate for infants (12 months and less).
Apart from the likelihood of both prevalence and intensity being
relatively low in infants in areas where soil-transmitted helminthi-
asis is endemic, there are questions of efficacy and safety when
using an anthelmintic drug in very young children [57]. Some
studies reveal that the no observed effect level/no observed
adverse effect level (NOEL/NOAEL) for ALB is 7 mg/kg/day
and that of MEB was found to be 7.8 and 8.4 mg/kg/day in males
and females, respectively in experimental animals [58]. Taking the
studied ALB tablets, it is possible to assess the associated risk due to
the overdosed assay values. The standard treatment guideline for
Ethiopia recommends 400 mg tablet as a single dose for treatment
of different helminths infections [58]. Assuming an average body
weight of 70 kg (body mass index: 23 and height: 175 cm), the
NOEL/NOAEL value for ALB can be calculated to be 490 mg
per day (taking a safety factor of 1), equivalent with 122.5%lc for a
400 mg tablet. All the assay values for ALB drug products were
Table 8. Association between the test results and areas of collection, types of drug outlets, and countries of origin.
Variable Registered quality failure P- value
Place of collection (number of samples) 0.07
Assosa (14) 4/14 (28.6%)
Hawasa (19) 3/19 (15.8%)
Addis Ababa (20) 10/20 (50.0%)
Jimma (16) 10/16 (62.5%)
Adama (18) 9/18 (50.0%)
Bahirdar (11) 6/11 (54.5%)
Mekele (8) 6/8 (75.0%)
Total (106) 48/106 (45.3%)
Drug outlets (number of samples) 0.46
Wholesale (5) 1/5 (20.0%)
Pharmacy (46) 24/46 (52.2%)
Drug stores (55) 23/55 (41.8%)
Total (106) 48/106 (45.3%)
Origin (number of samples) 0.04
Ethiopia (48) 21/48 (43.6%)
India (28) 11/28 (39.3%)
Cyrus (15) 8/15 (53.3%)
China (6) 6/6 (100.0%)
Korea (9) 2/9 (22.2%)
Total (106) 48/106 (45.3%)
doi:10.1371/journal.pntd.0003345.t008
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found to be less than or equal to 111.0%lc, indicating absence of
clinically significant risk for the ALB overdosed formulation
related to adverse effects. For MEB, since the treatment guideline
recommends 200 mg per day [59] and the NOEL/NOAEL value
is much higher, the over-dose in the assay values is not a direct
clinical concern related to adverse effects.
The assay distribution of the analyzed TNZ samples was found
to be from 86.1 to 120.6%lc. Considering the 2 g single dose
regimen of TNZ for treatment of giardiasis and the high level
NOEL/NOAEL value of 150 mg/kg together with the relative
clinical safety of TNZ, the over-dose in the assay values is also not
a direct clinical concern related to the adverse effects.
Under-dosing, which could be caused by degradation due to
inappropriate storage conditions, might pose toxicity risks due to
the degradant impurities. It can be one of the risk factors for the
development of anthelmintic resistance. Sub-optimal regimens are
the rule in human treatment: anthelmintics are administered in
single doses that never achieve 100% efficacy. Taking into account
the limited efficacy of single dose anthelmintic treatments, the
currently recommended regimens could constitute a significant
contributing factor to the development of anthelmintic resistance
in STH [60]. In addition to the single dose regimen, the
substandard drugs with content less than 90%lc, could further
exacerbate the problem of drug resistance leading to treatment
failure. Therefore, the risk of development of drug resistance to
MEB is higher than the other two drugs, ALB and TNZ since four
of the six under-dosed substandard drug samples were MEB.
Risk-based approach to medicines quality
FMEA is a well-known assessment tool used to identify the
critical components most likely to cause failures and to enhance
system reliability, through the development of suitable corrective
and preventive actions (CAPAs) [61]. Typically, the criticality is
evaluated either with the criticality number (CN), or with the risk
priority number (RPN). Although the CN is considered more
consistent and accurate, the RPN approach is generally preferred,
especially for its easiness of use [62], where the higher RPN values
indicate the criticality of the quality attribute.
The desirability function and its application in evaluation
of quality of medicines
Optimizing parameters is a critical issue during the develop-
ment of any method and/or product. A special set of functions
called desirability functions have been used in optimizing methods
[63,64] and products characteristics [65,66]; but the application of
such desirability functions for the assessment of the quality of
pharmaceutical products is new.
The overall desirability function D is obtained from the
individual desirabilities (di) using Equation 2. It can provide a
way to assess the quality according to one property, the overall D-
value. By mapping all properties onto a desirability scale between
0 and 1, the individual desirability scores due to multiple
properties may be easily combined as a geometric mean even if
the properties have different scales or units of measurement [67].
In the calculation of the overall D-value using Equation 2, pi = 3
was used for assay since quality risk associated to it was found to be
more important (RPN = 512). Similarly, pi = 2 was used for
dissolution since the risk associated with dissolution was of more
concern (RPN = 336) than others. For each of identity and dosage
uniformity, pi = 1 was assigned. The risk assessment revealed that
friability was not critically important with calculated RPN value of
only 2 and thus was not considered for the desirability study.
The risk analysis conducted indicated that the failure effects due
to the failure modes (non-complying quality attributes) was found
to be almost similar for the three products analyzed. For example,
for all, the over-dose in the assay values was evaluated to be not a
direct clinical concern related to the adverse effects. Moreover,
since all the three drugs are in BCS class II [26], dissolution is
equally a concern. Therefore, the same Derringer’s desirability
function was applied to all the drug products.
In general, comparing the two quality evaluation approaches, it
is reported that 29.2% of the samples were of poor quality when
using the pharmacopoeial method of quality evaluation, while it is
28.3% using the new innovative risk-based desirability function
approach. Even though it seems that there is no discrepancy
between the results of the conventional and D-function approach,
we still want to argue that the D-approach provides more weight
to the clinically more critical quality attributes and thus fit-for-
purpose in resource-limited economies. Resources could thus be
prioritized and reliable decisions can be made on the available
data using only the clinically more critical quality attributes (assay
and dissolution) than the less critical ones (friability and
disintegration tests). Moreover, the new QbD and risk-based
approach will less heavily penalize marginal out-of-specification
medicines, and therefore, we believe it is especially important for
poor-resource countries.
In conclusion, this study indicated that all sampled products
(MEB, ALB and TNZ) did contain the stated active ingredient, but
poor quality products were identified in all three medicines and
collection sites in the country due to non-compliant assays,
inadequate drug release of required dose or toxicity concerns due
to over-dosage of some of the medicines containing higher level of
active ingredient. Over-dose in the assay values of the three
studied drugs is not a direct clinical concern related to adverse
effects where as under-dosing constituted one of the risk factors for
the development of resistance.
The study further identified the most critical quality attributes in
product quality assessment using FMEA risk-based quality
evaluation of the three drugs where assay was found to be the
most critical quality attribute with highest RPN. Moreover, it was
revealed that Derringer’s desirability function can be applied to
pharmaceutical quality assessment using Psychophysical Harring-
ton’s scale of quality where products could be classified into
excellent, good, acceptable, low and bad quality.
Our study suggests policy strategies of containing the problems
related to poor quality medicines using this proactive risk-based
and desirability function approaches in nation-wide surveillance of
the quality of medicines circulating in their respective markets.
Furthermore, other possible strategies for containing the problem
of these poor quality medicines are e.g.:
N strengthening the capacity of drug regulatory authorities for
quality assurance and quality control activities;
N harmonization and regional sharing of information about
manufacturing and distribution quality;
N enforcement of regulations and legal prosecutions;
N empowerment and capacity building of medicines inspectors;
N continuous inspection and monitoring of the different levels of
medicines supply chain;
N continuous and sustainable product quality surveillance studies
with strong monitoring and evaluation activities
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